RxDoctor Payments Data

Sheri Greene, PA

Physician Assistant · Oklahoma City, OKNPI 1043215593

Payments from drug & device makers

$2,708in general payments, 2019–2025

Across 122 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$577
  • E.r. Squibb & Sons, L.L.C.$468
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$300
  • Abbott$233
  • Johnson & Johnson$220
  • Amgen$171
  • plus $741 from 15 others

What the payments were for

  • Food & beverage$2,708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,708 in reported general payments places this provider in the 80th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$3,878
Medicare patients
40
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$42,183
JardianceEmpagliflozin48$28,797
EntrestoSacubitril/Valsartan35$28,166
CorlanorIvabradine Hcl11$6,712
Metoprolol Succinate81$1,155
Valsartan38$1,116
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$761
Hydralazine Hcl36$747
Atorvastatin Calcium37$681
Carvedilol68$495
Losartan Potassium33$442
Flecainide Acetate27$427
Lisinopril38$421
Isosorbide Mononitrate ErIsosorbide Mononitrate16$249
Doxazosin Mesylate12$208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$42,18355 claims
Boehringer IngelheimJardiance$86$28,79748 claims
NovartisEntresto$121$28,16635 claims
AmgenCorlanor$171$6,71211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →